Sei Investments Co. Boosts Stake in TransMedics Group, Inc. $TMDX

Sei Investments Co. raised its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 25.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 69,629 shares of the company’s stock after purchasing an additional 14,338 shares during the period. Sei Investments Co.’s holdings in TransMedics Group were worth $6,922,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of TMDX. Harvest Fund Management Co. Ltd bought a new stake in TransMedics Group in the 3rd quarter worth approximately $29,000. Allworth Financial LP grew its position in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. Parallel Advisors LLC grew its position in TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after acquiring an additional 83 shares during the last quarter. Ascentis Independent Advisors purchased a new position in shares of TransMedics Group during the first quarter worth approximately $30,000. Finally, North Star Investment Management Corp. purchased a new position in shares of TransMedics Group during the first quarter worth approximately $30,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TMDX shares. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Stifel Nicolaus boosted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, June 18th. UBS Group assumed coverage on shares of TransMedics Group in a research report on Tuesday, July 28th. They set a “neutral” rating and a $80.00 price target for the company. Finally, Needham & Company LLC reduced their price objective on TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a research note on Monday. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $126.27.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $81.55 on Tuesday. The company has a market capitalization of $2.82 billion, a P/E ratio of 18.53 and a beta of 1.90. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The stock has a 50 day moving average price of $72.81 and a two-hundred day moving average price of $100.15.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the prior year, the business posted $0.70 EPS. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. Analysts expect that TransMedics Group, Inc. will post 1.88 earnings per share for the current year.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by corporate insiders.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.